In a bid to combat obesity and unemployment, the UK govt is collaborating with Eli Lilly, which will invest £279 mn in a ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.